+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and efficacy of intravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapy in participants with high-grade Bacillus Calmette-Guerin BCG unresponsive non-muscle invasive bladder cancer NMIBC with carcinoma in situ CIS high-grade TaT1. This pivotal phase 3 trial builds on prior findings where 53.4% of subjects achieved a complete response at 3 months, aiming to offer new options for patients unlikely to benefit from further BCG treatment. Participants are randomly assigned to one of two study groups nadofaragene firadenovec alone or nadofaragene firadenovec combined with sequential intravesical gemcitabine and docetaxel chemotherapy. The trial originally included a third arm with pembrolizumab infusion, but this arm is closed to new participants. Treatment involves intravesical bladder instillation of the study drugs, with pembrolizumab delivered by intravenous infusion for patients already enrolled in that arm. During the study, participants undergo regular assessments including evaluations of complete response at 3 and 6 months, durability of response up to 24 months, monitoring for disease progression, cystectomy-free survival, pathological staging, and overall survival up to 36 months. Safety is monitored through adverse event tracking. Participants are expected to be available for the entire study duration, which extends to 2030, allowing long-term observation of treatment effects and disease status.

Age: 18Years +All GendersPhase 3
81 locations
R

Actively Recruiting

Researchers are conducting a phase 3b randomized, controlled trial to compare nadofaragene firadenovec versus observation in participants with intermediate risk non-muscle invasive bladder cancer IR NMIBC. The study aims to evaluate treatment effects on recurrence-free survival over a 24-month period. This trial is sponsored by Ferring Pharmaceuticals and focuses on participants who have undergone prior tumor resection and meet specific risk criteria according to established urological guidelines. Participants assigned to the nadofaragene firadenovec group will receive quarterly instillations of this vector-based gene therapy designed to boost the bodys interferon alfa-2b response for up to 24 months. Those in the observation group will be followed according to routine surveillance schedules recommended by the American Urological Association AUA and the Society of Urologic Oncology SUO, also on a quarterly basis for 24 months. Disease evaluations for treated participants will occur within two weeks prior to each treatment instillation. Throughout the study, participants will undergo regular disease evaluations and monitoring for adverse events up to 24 months. Researchers will measure recurrence-free survival at 12 and 24 months as primary and secondary outcomes. The trial design includes randomized allocation without masking, and participants will be followed during the treatment period and beyond for safety and efficacy assessments, with total participation lasting up to 24 months.

Age: 18Years +All GendersPhase 3
116 locations